A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Guidong Zhu
SparX Biotech
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Phoenix, Arizona, United States
Mitesh Borad, MDRecruiting - Honorhealth Research and Innovation Institute
Scottsdale, Arizona, United States
Justin Moser, MDRecruiting - Mayo Clinic Florida
Jacksonville, Florida, United States
Yujie Zhao, MD PhDRecruiting - Mayo Clinic Rochester
Rochester, Minnesota, United States
Hao Xie, MD PhDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Mar 2024
- Primary completion
- 30 Sept 2027
- Completion
- 30 Sept 2027
- Last update posted
- 24 Sept 2024
- Registered enrollment
- 232
- Registry id
- NCT06259552
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.